Alefacept was the first biologic therapy approved for the treatment of chronic plaque psoriasis in Canada.
Objective
The AWARE study was an observational phase IV study whose main goal was to describe the outcomes of alefacept treatment in a broad population of Canadian psoriasis patients.
Methods
A total of 426 patients with chronic plaque psoriasis were enrolled from 37 clinics across Canada. Patients were treated with up to two courses of alefacept and followed for up to 60 weeks.
Results
The majority of patients had a moderate to marked response to alefacept treatment. Treatment with concomitant systemic therapy was discontinued or reduced in up to a third of subjects. Forty percent completed the entire follow-up period without receiving a second course of alefacept.
Conclusion
In routine clinical settings in Canada, alefacept is an effective and safe option for the treatment of a wide range of patients with psoriasis.
JenneckC., NovakN.The safety and efficacy of alefacept in the treatment of chronic plaque psoriasis. Ther Clin Risk Manag.2007; 3(3): 411–20.
2.
BrimhallA.K., KingL.N., LicciardoneJ.C., Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. Br J Dermatol.2008; 159: 274–85.
3.
KruegerG., KooJ., LebwohlM.The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol.2001; 137: 280–4.
4.
National Psoriasis Foundation. National Psoriasis foundation 2008 Survey Panel Snapshot. Available at http://psoriasis.org/survey. Accessed on November 30, 2009.
5.
Astellas Pharma Canada Inc.Amevive™ Product Monograph, June 1, 2006.
6.
EllisC.N., KruegerG.G., for the Alefacept Clincal Study Group. Treatment of chronic plaque psoriasis by selective targeting of memory effector lymphocytes. N Engl J Med.2001; 345: 248–55.
7.
LangleyR.G., GordonK.B.Duration of remission of biologic agents for chronic plaque psoriasis. J Drugs Dermatol.2007; 6: 1205–12.
8.
PerlmutterA., CatherJ., FranksB., JaraczE., MenterA.Alefacept revisited: our 3-year clinical experience in 200 patients with chronic plaque psoriasis. J Am Acad Dermatol.2008; 58: 116–24.
9.
LebwohlM., ChristophersE., LangleyR.An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol.2003; 139: 719–27.
10.
GordonK.B., LangleyR.G.Remittive effects of intramuscular alefacept in psoriasis. J Drugs Dermatol.2003; 2: 624–8.
11.
KruegerG.G., PappK.A., StoughD.B.A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol.2002; 47(6): 821–33.
12.
MenterA., CatherJ.C., BakerD.The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis. J Am Acad Dermatol.2006; 54: 116–24.
13.
KruegerG.G., GottliebA.B., SterryW.A multicenter, open-label study of repeat courses of intramuscular alefacept in combination with other psoriasis therapies in patients with chronic plaque psoriasis. J Dermatol Treat.2008; 19: 146–55.
14.
GribetzC.H., BlumR., BradyC.An extended 16-week course of alefacept in the treatment of chronic plaque psoriasis. J Am Acad Dermatol.2005; 53: 73–5.
15.
WeismanS., PollackC.R., GottschalkR.W.Psoriasis disease severity measures: comparing efficacy of treatment for severe psoriasis. J Dermatol.2003; 14: 158–65.
16.
LebwohlM., MenterA., KooJ., FeldmanS.R.Combination therapy to treat moderate to severe psoriasis. J Am Acad Dermatol.2004; 50: 416–30.
17.
OrtonneJ.P.Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venerol.2003; 17(S2): 12–16.
18.
MeaseP.J., GladmanD.D., KeystoneEC; Alefacept in Psoriatic Arthritis Study Group. Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum.2006; 54: 1638–45.
19.
MeaseP.J., ReichKE; Alefacept in Psoriatic Arthritis Study Group. Alefacept with methotrexate for treatment of psoriatic arthritis: Open-label extension of a randomized, double-blind, placebo-controlled study. J Am Acad Dermatol.2008; Nov 22 [Epub ahead of print].
20.
CarrD., TusaM.G., CarrolC.L.Open label trial of alefacept in palmoplantar pustular psoriasis. J Dermatol Treat.2008; 19: 97–100.
21.
ParrishC.A., SoberaJ.O., RobbinsC.M.Alefacept in the treatment of psoriatic nail disease: a proof of concept study. J Drugs Dermatol.2006; 5: 339–40.
22.
LangleyR.G., ChermanA.M., GuptaA.K.Alefacept: an expert review concerning the treatment of psoriasis. Exp Opin Pharmacother.2005; 6: 2327–33.
23.
GuentherL., LangleyR.G., ShearN.H.Integrating biologic agents into management of moderate-to-severe psoriasis: a consensus of the Canadian Psoriasis Expert Panel. J Cutan Med Surg.2004; 8: 321–37.
24.
KormanN.J., MoulD.K.Alefacept for the treatment of psoriasis: a review of the current literature and practical suggestions for everyday clinical use. Sem Cutan Med Surg.2005; 24: 10–18.
25.
McClureS.L., ValentineJ., GordonK.B.Comparative tolerability of systemic treatments for plague-type psoriasis. Drug Saf.2002; 25: 913–27.
26.
NaldiL., GriffithsC.E.M.Traditional therapies in the management of moderate to severe chronic plague psoriasis: an assessment of the benefits and risks. Br J Dermatol.2005; 152: 597–615.
27.
KooJ.Y., BagelJ., SweetserM.T., TichoB.S.Alefacept in combination with ultraviolet B phototherapy for the treatment of chronic plague psoriasis: results from an open-label, multicenter study. J Drugs Dermatol.2006; 5: 623–8.
28.
LegatF.J., HoferA., WackernagelA.Narrowband UV-B phototherapy, alefacept and clearance of psoriasis. Arch Dermatol.2008; 144: 1067–8.
29.
OrtonneJ.P., KhemisA., KooJ.Y.M., ChoiJ.An open-label study of alefacept plus ultraviolet B light as combination therapy for chronic plague psoriasis. J Eur Acad Dermatol Venerol.2005; 19: 556–63.
30.
ZeichnerJ.A., LebwohlM.Potential complications associated with the use of biologic agents for psoriasis. Dermatol Clin.2007; 25: 207–13, VII.
31.
EMD Serono Canada Inc. Healthcare Professional Communication: Health Canada Recommendation to Suspend RAPTIVA® (efalizumab) in Canada. February 20, 2009.
32.
GoffeB., PappK., GrattonK.An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy. Clin Ther.2005; 27(12): 1912–21.
33.
WalshS.R.A., ShearN.H.Psoriasis and the new biologic agents: interrupting a T-AP dance. CMAJ.2004; 170: 1933–41.
34.
GordonK.B., VaishnawA.K., O'GormanJ.; for the Alefacept Clinical Study Group. Treatment of psoriasis with alefacept: correlation of clinical improvement with reduction in memory T-cell counts. Arch Dermatol.2003; 139: 719–27.
35.
RicoM.J., KrellJ.M., BagelJ.Assessment and tracking of long-term alefacept safety (ATLAS): analysis of data from approximately 1200 patients. Poster presented at the 21st World Congress of Dermatology, 30 September – 5 October 2007, Buenos Aires, Argentina: P5237.
